Scarica l'app Stockscreener
2.18
14.00%
-0.355
Dopo l'orario di chiusura:
2.18
Precedente Chiudi:
$2.535
Aprire:
$2.18
Volume 24 ore:
105.41K
Relative Volume:
0.60
Capitalizzazione di mercato:
$204.71M
Reddito:
$3.13M
Utile/perdita netta:
$-55.77M
Rapporto P/E:
-3.5476
EPS:
-0.6145
Flusso di cassa netto:
$-61.24M
1 W Prestazione:
+26.01%
1M Prestazione:
+21.79%
6M Prestazione:
+25.29%
1 anno Prestazione:
+0.19%
Intervallo 1D:
$2.1216
$2.24
Intervallo di 1 settimana:
$2.07
$2.71
Portata 52W:
$1.17
$2.71
Innate Pharma Adr Stock (IPHA) Company Profile
Nome
Innate Pharma Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare IPHA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.18 | 231.94M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-09-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | Iniziato | BTIG Research | Buy |
| 2021-09-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Iniziato | Goldman | Neutral |
Mostra tutto
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - sharewise.com
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
FY2026 EPS Estimates for Innate Pharma Reduced by Analyst - MarketBeat
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com South Africa
Innate Pharma plans phase 3 trial, names new medical officer - Investing.com
Innate Pharma partners with Sobi on lacutamab development - Investing.com
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com South Africa
Innate Pharma completes enrollment in IPH4502 phase 1 study - Investing.com
Innate Pharma completes enrollment in IPH4502 phase 1 study By Investing.com - Investing.com South Africa
IPHA Q1 2026 Earnings: Significant EPS Miss on R&D InvestmentsEPS Surprise History - po-news-eg.net
Form 13G Innate Pharma SA For: 22 June By Investing.com - Investing.com South Africa
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
IPHAInnate Pharma ADR Stock Price and Quote - Finviz
AUTLAutolus Therapeutics plc ADR Stock Price and Quote - Finviz
IPHA Technical Analysis | Trend, Signals & Chart Patterns | INNATE PHARMA SA-SPONS ADR (NASDAQ:IPHA) - ChartMill
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Innate Pharma Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts - Investing.com
Unusual VolumeStock ScreenerNews - Finviz
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Top GainersStock ScreenerSnapshot - Finviz
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com India
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline By Investing.com - Investing.com India
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
NASDAQ New 52-Week Highs And Lows - Moomoo
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Here’s What Happened - Defense World
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - ChartMill
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Innate Pharma Adr Azioni (IPHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):